Actavis | pharmaphorum

Skip to main content

Monday 12 January 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Actavis

News

supreme-court

Biotech association steps in to fight growth of ‘plausibilit...

The UK’s Supreme Court is to allow the UK BioIndustry Association (BIA) to intervene in a long-running legal battle over a drug patent.

News

pounds

Concordia and Actavis face UK pricing probe

Firms colluded to hike prices, says competition watchdog.

UK & Europe

Pfizer's Lyrica patent appeal fails in UK

Pfizer's Lyrica patent appeal fails in UK

Generics firms free to exploit gap in Pfizer's patent defences.

News

TevaCanada2

Teva's Allergan acquisition goes ahead

Part of UK business to be sold.

Editor's Picks

Servier signs €1bn-plus AI pact with Iktos

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Rumour confirmed as Lilly buys Ventyx for $1.2 billion

Court blocks HHS' 340B rebate programme pilot

Bayer's Monsanto sues mRNA COVID-19 vaccine makers

News

J&J chief executive Joaquin Duato

J&J jumps on the MFN pricing train

Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company